论文部分内容阅读
目的:探讨阿莫西林克拉维酸钾联合阿奇霉素治疗社区获得性肺炎(CAP)的临床疗效。方法:选取于2010年1月-2012年1月收治的CAP患者145例,采用随机数字表法将其分为两组,其中治疗组73例,对照组72例。治疗组给予阿莫西林克拉维酸钾联合阿奇霉素治疗,对照组只单纯给予应用阿莫西林克拉维酸钾。两组疗程均为7~14 d。于治疗后比较两组的临床疗效。结果:(1)治疗组治愈、显效、有效、无效分别为43例(58.9%)、16例(21.9%)、8例(11.0%)、6例(8.2%);对照组分别为20例(27.8%)、26例(36.1%)、14例(19.4%)、12例(16.7%)。两组疗效比较,差异有统计学意义(P<0.05)。(2)治疗组胃肠道反应、静脉滴注局部疼痛、皮疹的发生分别为6例(8.2%)、7例(9.6%)、3例(4.1%),总不良反应发生率为16例(21.9%);对照组分别为5例(6.9%)、6例(8.3%)、3例(4.2%)、14例(19.4%)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿莫西林克拉维酸钾联合阿奇霉素治疗CAP疗效好。
Objective: To investigate the clinical efficacy of amoxicillin and clavulanate combined with azithromycin in the treatment of community-acquired pneumonia (CAP). Methods: A total of 145 CAP patients admitted from January 2010 to January 2012 were enrolled in this study. They were divided into two groups according to the random number table method, including 73 cases in the treatment group and 72 cases in the control group. The treatment group was treated with amoxicillin and clavulanate potassium combined with azithromycin, while the control group only given amoxicillin and clavulanate potassium. The two courses of treatment were 7 to 14 days. After treatment, the clinical efficacy of the two groups were compared. Results: (1) In the treatment group, 43 cases (58.9%), 16 cases (21.9%), 8 cases (11.0%) and 6 cases (8.2%) were cured, (27.8%), 26 cases (36.1%), 14 cases (19.4%) and 12 cases (16.7%). The curative effect between the two groups, the difference was statistically significant (P <0.05). (2) The incidence of gastrointestinal pain, local pain and rash in the treatment group were 6 cases (8.2%), 7 cases (9.6%) and 3 cases (4.1%) respectively. The total incidence of adverse reactions was 16 (21.9%). The control group was 5 (6.9%), 6 (8.3%), 3 (4.2%) and 14 (19.4%) respectively. The incidence of adverse reactions in the two groups, the difference was not statistically significant (P> 0.05). Conclusion: Amoxicillin and clavulanate combined with azithromycin in the treatment of CAP is effective.